Daratumumab monotherapy for patients with relapsed or refractory natural killer/T-cell lymphoma, nasal type: an open-label, single-arm, multicenter, phase 2 study

Daratumumab monotherapy for patients with relapsed or refractory natural killer/T-cell lymphoma, nasal type: an open-label, single-arm, multicenter, phase 2 study

Abstract Background Natural killer/T-cell lymphoma (NKTCL) is a disease with limited treatment options and poor outcomes. Daratumumab monotherapy demonstrated clinical activity in a single-patient case report. We present data from the primary analysis of a phase 2 study of daratumumab monotherapy in...

Full description

Bibliographic Details
Main Authors: Huiqiang Huang, Jun Zhu, Ming Yao, Tae Min Kim, Dok Hyun Yoon, Seok-Goo Cho, Hyeon Seok Eom, Soon Thye Lim, Su-peng Yeh, Yuqin Song, Yok Lam Kwong, Jin Seok Kim, Jie Jin, Yuankai Shi, HyeJin Kim, Min Qing, Tianyuan Zhou, Grace Gao, Zongqi Dong, Ming Qi, Won Seog Kim
Format: Article
Language:English
Published: BMC 2021-02-01
Series:Journal of Hematology & Oncology
Subjects:
Daratumumab
NK/T-cell lymphoma
CD38
Online Access:https://doi.org/10.1186/s13045-020-01020-y

Internet

https://doi.org/10.1186/s13045-020-01020-y

Similar Items